MANAGE-PD and clinician recommendations for device-aided therapy in Parkinson's disease: Insights from a Turkish tertiary movement disorders cohort.

Among Category 3 patients, only 10 (14.7%) were recommended for device-aided therapies.

Patients receiving a clinician recommendation had significantly longer disease duration, higher levodopa equivalent daily dose, and were more likely to experience OFF periods exceeding 2 h per day and troublesome dyskinesia.

In exploratory multivariable analyses, disease duration (OR 2.29 per 5 years, 95% CI 1.34-3.91) and OFF periods exceeding 2 h per day (OR 6.80, 95% CI 1.67-27.75) remained independently associated with clinician recommendation.

Within the MANAGE-PD Category 3 subgroup, disease duration was the only factor associated with clinician device-aided therapies recommendation.